rociletinib and Adenocarcinoma

rociletinib has been researched along with Adenocarcinoma* in 2 studies

Other Studies

2 other study(ies) available for rociletinib and Adenocarcinoma

ArticleYear
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1

    Topics: Acrylamides; Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Pyrimidines; Treatment Outcome

2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-01, Volume: 22, Issue:19

    To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).. We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686). Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.

    Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrimidines

2016